DexCom, Inc. $DXCM Shares Acquired by J. Safra Sarasin Holding AG

Key Points

• J. Safra Sarasin Holding AG increased its holdings in DexCom, Inc. by 153.8%, owning 40,575 shares valued at approximately $3.54 million as of the latest reporting period.
• Despite recent insider sales, institutional investors hold 97.75% of DexCom's stock, reflecting strong institutional backing for the company.
• DexCom reported a 15.2% year-over-year increase in revenue for the quarter, with earnings per share of $0.48, surpassing analysts' expectations of $0.45.

J. Safra Sarasin Holding AG lifted its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 153.8% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 40,575 shares of the medical device company's stock after purchasing an additional 24,590 shares during the period. J. Safra Sarasin Holding AG's holdings in DexCom were worth $3,542,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in DXCM. Golden State Wealth Management LLC boosted its position in DexCom by 211.2% in the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after buying an additional 264 shares during the period. Zions Bancorporation National Association UT acquired a new stake in shares of DexCom in the first quarter valued at $27,000. Anderson Financial Strategies LLC purchased a new position in DexCom in the first quarter valued at $37,000. Alpine Bank Wealth Management purchased a new position in DexCom in the first quarter valued at $40,000. Finally, Private Trust Co. NA grew its stake in DexCom by 99.4% during the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock worth $46,000 after purchasing an additional 335 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $66.44 on Friday. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $93.25. The firm has a market capitalization of $26.05 billion, a P/E ratio of 46.14, a P/E/G ratio of 1.39 and a beta of 1.47. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. The company's fifty day moving average price is $76.75 and its 200 day moving average price is $77.91.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter in the prior year, the firm posted $0.43 earnings per share. DexCom's revenue for the quarter was up 15.2% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Transactions at DexCom

In other news, EVP Sadie Stern sold 1,466 shares of the stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $80.00, for a total value of $117,280.00. Following the completion of the sale, the executive vice president directly owned 105,223 shares of the company's stock, valued at approximately $8,417,840. This represents a 1.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Kyle Malady sold 667 shares of DexCom stock in a transaction on Friday, September 5th. The shares were sold at an average price of $80.86, for a total transaction of $53,933.62. Following the completion of the transaction, the director directly owned 22,667 shares in the company, valued at $1,832,853.62. The trade was a 2.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 6,849 shares of company stock worth $564,733 in the last three months. Corporate insiders own 0.32% of the company's stock.

Analyst Ratings Changes

DXCM has been the topic of a number of analyst reports. Robert W. Baird reduced their price target on DexCom from $112.00 to $90.00 and set an "outperform" rating on the stock in a research report on Friday, September 26th. Argus initiated coverage on shares of DexCom in a report on Thursday, August 21st. They issued a "buy" rating and a $100.00 target price on the stock. Raymond James Financial boosted their price target on shares of DexCom from $99.00 to $102.00 and gave the stock a "strong-buy" rating in a report on Thursday, July 31st. Truist Financial began coverage on shares of DexCom in a research report on Monday, June 16th. They issued a "buy" rating and a $102.00 price objective on the stock. Finally, Morgan Stanley lifted their price objective on shares of DexCom from $82.00 to $89.00 and gave the stock an "equal weight" rating in a research report on Tuesday, July 15th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $98.32.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.